Preliminary results show that, while Lagevrio hastened the time to recovery from COVID-19 by around six days, it was no better than placebo at keeping patients out of hospital.

Lagevrio (molnupiravir) added $3.2 billion to Merck's top line of $15.9 billion, but even without the drug sales would have risen 19% thanks to a strong performance from cancer immunotherapy ...

The remaining Xocova tablets produced by Shionogi & Co., Lagevrio capsules made by Merck & Co. and Paxlovid pills manufactured by Pfizer Inc., estimated to be worth 300 billion yen ($1.93 billion ...

Cat owners in China desperate to save their beloved cats are using human COVID-19 drugs like Merck’s Lagevrio to treat Feline Infectious Peritonitis (FIP)—a deadly disease in cats that earlier ...